Ac-SDKP is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
(CH2CH2)O + RCOCl + NaI → RC(O)–OCH2CH2–I + NaCl Heating ethylene oxide to 100 °C with carbon dioxide, in a non-polar solvent in the presence of bis-(triphenylphosphine)-nickel(0) results in ethylene carbonate:
Norbert Elias; (1897-1990) sociologist especially famous for theory of civilising/decivilising processes; was deeply involved in the German Zionist movement, and acted as one of the leading intellectuals within the German-Jewish youth movement "Blau-Weiss" (Blue-White). Elias' most famous work is The Civilizing Process Samantha Ellis is an Iraqi Jewish British playwright and writer best known for her books How to be a Heroine, Chopping Onions on My Heart, and her play How to Date a Feminist. Richard Ellmann literary scholar and biographer Aaron Esterson (23 September 1923 – 15 April 1999) prolific author and psychiatrist who was one of the founders of the Philadelphia Association along with R. D. Laing, with whom he wrote Sanity, Madness, and the Family. He wrote four other scholarly texts on psychiatry and existentialism as well as countless academic papers and monographs. Hans Eysenck (4 March 1916 – 4 September 1997); author of over fifty books and numerous academic papers; of German Jewish maternal lineage; psychologist best remembered for his work on intelligence and personality, although he worked on other issues in psychology. At the time of his death, Eysenck was the most frequently cited living psychologist in the peer-reviewed scientific journal literature. Henry Ezriel (c1910-1985) was a Kleinian analyst and author who pioneered group analysis at the Tavistock Clinic; best known as the originator of one of the Malan triangles; worked alongside W. R. Bion as consultant psychiatrist to the Tavistock.
=== Movement === In addition to the formation of lamellipodia and filopodia, intracellular concentration and cross-talk between different Rho proteins drives the extensions and contractions that cause cellular locomotion. Sakumura et al. proposed a model based on differential equations that helps explain the activity of Rho proteins and their relationship to motion. This model encompassed the three proteins Cdc42, RhoA, and Rac. Cdc42 was assumed to encourage filopodia elongation and block actin depolymerization. RhoA was considered to encourage actin retraction. Rac was treated to encourage lamellipodia extension but block actin depolymerization. These three proteins, although significantly simplified, covered the key steps in cellular locomotion. Through various mathematical techniques, solutions to the differential equations that described various regions of activity based on intracellular activity were found. The paper concludes by showing that the model predicts that there are a few threshold concentrations that cause interesting effects on the activity of the cell. Below a certain concentration, there is very little activity, causing no extension of the arms and feet of the cell. Above a certain concentration, the Rho protein causes a sinusoidal oscillation much like the extensions and contractions of the lamellipodia and filopodia. In essence, this model predicts that increasing the intracellular concentration of these three key active Rho proteins causes an out-of-phase activity of the cell, resulting in extensions and contractions that are also out of phase.
Sources: en.wikipedia.org
==== Cyclodextrin-type CSP ==== Cyclodextrins (CDs) are cyclic oligosaccharides of six, seven, or eight glucose units designated as α, β, and γ cyclodextrins respectively. Depicted in the diagram below. Daniel Armstrong is considered the pioneer of micelle and cyclodextrin-based separations. Cyclodextrins are covalently attached to silica by Armstrong process and provide stable CSPs. The primary hydroxyl groups are used to anchor the CD molecules to the modified silica surface. CDs are chiral because of innate chirality of the building blocks, glucose units. In cyclodextrin the glucose units are α-(1,4)- connected. The shape of CD looks like a shortened cone (see the sketch). The inner surface of the cone forms moderately hydrophobic pocket. The width of the CD-cavity is identified with the quantity of glucose units present. In cyclodextrins, secondary hydroxyl groups (OH-2 and - 3) line the upper rim of the cavity, and an essential 6-hydroxyl group is positioned at the lower rim. The hydroxyl group offer chiral binding points, which appear to be fundamental for enantioselectivity. Apolar glyosidic oxygen makes the pit hydrophobic and guarantees inclusion complexing of the hydrophobic moiety of analytes. Interactions between the polar area of an analyte and secondary hydroxyl groups at the mouth of the pit, joined with the hydrophobic connections inside the pit, give a unique two-point fit and lead to enantioselectivity.
=== Alphabet methods === A special class of protein structural alignment programs convert the input structure into a sequence of letters describing the structure. This allows methods from sequence alignment to be translated into this field to enable more efficient searching, and in some implementations, to also align and superimpose in real 3D space.
== Career == Working first in the Physical Chemistry Laboratory, he moved to the Dunn Nutritional Laboratory, and in 1938 moved to Wool Industries Research Institution in Leeds. He was head of the biochemistry division of Boots Pure Drug Company from 1946 to 1948, when he joined the Medical Research Council. There, he was appointed head of the physical chemistry division of the National Institute for Medical Research in 1952, and was chemical consultant from 1956 to 1959. He specialised in biochemistry, in some aspects of vitamins E and B2, and in techniques that laid the foundation for several new types of chromatography. He developed partition chromatography whilst working on the separation of amino acids, and later developed gas-liquid chromatography with Anthony T. James. Amongst many honours, he received his Nobel Prize in 1952. After his retirement from the University of Sussex, he was visiting professor at both the University of Houston in Texas and the EPFL (École Polytechnique Fédérale de Lausanne) in Switzerland. He published far fewer papers than the typical Nobel winners—only 70 in all—but his ninth paper contained the work that would eventually win him the Nobel Prize. The University of Houston dropped him from its chemistry faculty in 1979 (when he was 69 years old) because he was not publishing enough.
Topical gels are commonly used as sustained release dosage forms. Usage of the sustained release dosage form reduces the administration of recurrent doses while maintaining serum dose levels within the therapeutic range (the range between the minimum effective dose and the minimum toxic dose), hence improving patient compliance. Some topical gels are fast release gels, which are highly absorbent and can swell rapidly. These fast release gels can be used to treat acute disorders. Topical gels are also used as lubricants, or carriers for pharmaceutical agents. They can be used as vehicles for different purposes, via different routes of administration, such as dental, dermatologicall, ophthalmic, intranasal, vaginal, rectal and others. Topical gels are commonly used in cosmetics, which include shampoos, dentifrices, skin and hair care formulations and fragrance products, and can be used to treat scalp inflammation. Topical gels can be used to deliver anti-inflammatory steroids to the scalp in treatment of scalp inflammations.
Sources: en.wikipedia.org
2020 Indian agriculture acts Atal Bhujal Yojana E-NAM for online agrimarketing Gramin Bhandaran Yojana for local storage Micro Irrigation Fund (MIF) National Mission For Sustainable Agriculture (NMSA) National Scheme on Fisheries Training and Extension National Scheme on Welfare of Fishermen Pradhan Mantri Kisan Samman Nidhi (PMKSN) for minimum support scheme Pradhan Mantri Krishi Sinchai Yojana (PMKSY) for irrigation Paramparagat Krishi Vikas Yojana (PKVY) for organic farming Pradhan Mantri Fasal Bima Yojana (PMFBY) for crop insurance In July 2025, the Union Cabinet raised the outlay for the Pradhan Mantri Kisan Sampada Yojana (PMKSY) to ₹6,520 crore, including ₹1,920 crore additional funding for the 15th Finance Commission cycle. The approval supports 50 food irradiation units and 100 NABL-accredited food testing labs under the scheme’s cold chain and food safety components.
After optimizing the concentration of graphene oxide concentration and anisotropic porous structure, tensile tests were performed. It was found that MGCA could recover 99.8% and 96.3% when compressed to 60% and 90% strain, respectively. SEM images showed that due to its unique structure, MCGA pore walls were able to wrinkle and fold during compression. Another unique characteristic of this material is its absorption capacity of 80-197 times its weight towards hydrophobic compounds, such as oils and chemical solvents. On the contrary, less effort has been made to study the stretchability of porous carbons. Gao, et al. synthesized a long-range lamellar scaffold composed of chitosan and graphene oxide via bidirectional freezing, freeze drying, and annealing. The result is a material with density of 11 mg cm−3 and porosity of about 99.4%. Various tensile tests were conducted, and it was found that carbon spring could revert to its original shape upon 80% compression strain and -60% stretching strain with a Poisson's ratio between 0.05 and 0.1. The narrow hysteresis loop of the stress-strain curve indicates a low energy dissipation (energy loss coefficient of about 0.2) because of its negligible interior friction, localized buckling, or cracks during deformation processes. The stretchable mechanical properties of this material allow for great candidates for vibrational and magnetism sensors.
==== MeSH D13.444.600 – nucleic acid probes ==== MeSH D13.444.600.150 – antisense elements (genetics) MeSH D13.444.600.150.200 – DNA, antisense MeSH D13.444.600.150.200.640 – oligodeoxyribonucleotides, antisense MeSH D13.444.600.150.640 – oligonucleotides, antisense MeSH D13.444.600.150.640.640 – oligodeoxyribonucleotides, antisense MeSH D13.444.600.150.640.645 – oligoribonucleotides, antisense MeSH D13.444.600.150.760 – rna, antisense MeSH D13.444.600.150.760.640 – oligoribonucleotides, antisense MeSH D13.444.600.223 – DNA probes MeSH D13.444.600.223.500 – DNA, complementary MeSH D13.444.600.223.550 – DNA probes, hla MeSH D13.444.600.223.555 – DNA probes, hpv MeSH D13.444.600.601 – oligonucleotide probes MeSH D13.444.600.723 – rna probes MeSH D13.444.600.723.480 – rna, complementary
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.